Efficacy and safety of simeprevir plus pegylated intereferon combination therapy for HCV genotype 1 patients with chronic renal failure
Not Applicable
- Conditions
- chronic infection with hepatitis C virus
- Registration Number
- JPRN-UMIN000012668
- Lead Sponsor
- Osaka University Graduate school of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with co-infection with hepatitis B virus or human immunodeficiency virus or alcoholic liver disorder or autoimmune hepatitis. 2) Patients with uncompensated cirrhosis or hepatic failure 3) Patients with multiple organ failure or immunological deficiency 4) Patients with severe depression or past history of psychiatric disorder 5) Patients in pregnancy or lactating or patients who expect to become pregnant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Investigating sustained virological response rate (the rate of undetectable HCV RNA at end of treatment and at 24 weeks after completion of treatment) of Simeprevir plus Peg-IFN combination therapy in HCV genotype 1 patients with chronic renal failure. - Investigating the factors for sustained virological response.
- Secondary Outcome Measures
Name Time Method